Study details
Enrolling now
Psilocybin for Cancer Pain
Yvan Beaussant, MD, MSci
NCT IDNCT06001749ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
15
Study length
about 2.3 years
Ages
18+
Locations
1 site in MA
What this study is about
Researchers are testing whether psilocybin can help reduce pain in people with advanced cancer who are not responding to opioids. The trial will last about 830 days and involve approximately 15 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Psilocybin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
oral
Endpoints
Secondary: Change in Pain Catastrophizing Score from Baseline, Change in Pain Intensity Score from Baseline, Change in Pain Interference Score from Baseline
Body systems
Psychiatry / Mental Health